Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy

Chin, S.; Poey, Alfred C.; Wong, Chee-Yin; Chang, Sau-Kong; Tan, Chiang-Soo; Ng, Mei-Theng; Chew, Kee-Hock; Lam, Kai-Huat; Cheong, Soon-Keng

doi:10.3109/14653249.2011.574118

Cited by 31 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the study demonstrated that Ixmyelocel-T intramyocardial injection reduced major adverse cardiovascular events and improved symptoms in patients with ischemic dilated cardiomyopathy but not in patients with nonischemic dilated cardiomyopathy [56]. Whether it be intramyocardial, intracoronal, or transendocardial administration of autologous BMSSCs in cases of chronic heart disease, has demonstrated safety and improved clinical outcomes in parameters of left ventricular function [57,58]. Additionally, it has been suggested that BMSSC treatment not only improves function and clinical symptoms, but also slows down disease progression.…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Bone Marrow Stromal Stem Cells in Tissue Engineering and Regenerative Medicine

2016

View full text Add to dashboard Cite

Bone marrow stromal stem cells (BMSCs) are adult multipotent cells, which have the potential to differentiate into cell types of mesodermal origin, namely osteocytes, adipocytes, and chondrocytes. Due to their accessibility and expansion potential, BMSCs have historically held therapeutic promise in tissue engineering and regenerative medicine applications. More recently, it has been demonstrated that not only can bone marrow stromal stem cells directly participate in tissue regeneration, but they also have the capacity to migrate to distant sites of tissue injury, where they can participate in tissue repair either directly through their differentiation or indirectly through paracrine mechanisms. Additionally, they can elicit various immunomodulatory signals, which can attenuate the inflammatory and immune responses. As such, bone marrow stromal stem cells have been explored clinically for treatment of a wide variety of different conditions including bone defects, graft-vs.-host disease, cardiovascular diseases, autoimmune diseases, diabetes, neurological diseases, and liver and kidney diseases. This review provides an overview of current clinical applications of bone marrow stromal stem cells and discusses their therapeutic properties, while also addressing limitations of their use. PubMed, Ovid, and Google Scholar online databases were searched using several keywords, including "stem cells", "tissue engineering", tissue regeneration" and "clinical trials". Additionally, Clinical trials.gov was used to locate completed clinical trials using bone marrow derived stem cells.

show abstract

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Bone Marrow Stromal Stem Cells in Tissue Engineering and Regenerative Medicine

2016

View full text Add to dashboard Cite

show abstract

“…These studies have been proven to be generally safe and feasible without notable side effects; moreover, patients receiving BM-MSC therapy have experienced clinical benefits mainly in terms of scar reduction, a decrease in arrhythmias, an attenuation of ventricular contraction dysfunctions and an increase in left ventricular ejection fraction [92,93,94,95,96,97,98,99]. …”

Section: Bone Marrow-derived Mesenchymal Stromal Cells (Bm-mscs)mentioning

confidence: 99%

Trophic Actions of Bone Marrow-Derived Mesenchymal Stromal Cells for Muscle Repair/Regeneration

Sassoli

Zecchi‐Orlandini

Formigli

2012

Cells

View full text Add to dashboard Cite

Bone marrow-derived mesenchymal stromal cells (BM-MSCs) represent the leading candidate cell in tissue engineering and regenerative medicine. These cells can be easily isolated, expanded in vitro and are capable of providing significant functional benefits after implantation in the damaged muscle tissues. Despite their plasticity, the participation of BM-MSCs to new muscle fiber formation is controversial; in fact, emerging evidence indicates that their therapeutic effects occur without signs of long-term tissue engraftment and involve the paracrine secretion of cytokines and growth factors with multiple effects on the injured tissue, including modulation of inflammation and immune reaction, positive extracellular matrix (ECM) remodeling, angiogenesis and protection from apoptosis. Recently, a new role for BM-MSCs in the stimulation of muscle progenitor cells proliferation has been demonstrated, suggesting the potential ability of these cells to influence the fate of local stem cells and augment the endogenous mechanisms of repair/regeneration in the damaged tissues.

show abstract

“…It was already shown that intravenously infused MSC are safe and efficacious in treatment of myocardial infarctions [96]. There are also clinical trials in which MSC were administered intracoronary [97,98] or intramyocardially [97]. However in many trials homing and engraftment of MSC into the heart was not studied.…”

Section: Msc Migration Towards the Heartmentioning

confidence: 96%